Articles

Find an Article

Filter articles

Applied Filters

Showing 201 to 210 of 272 results

Momentum building for the UPC

EU, France, Germany, UK19-02-2015Paul England

The unitary patent and Unified Patent Court will have wide-ranging implications for life sciences companies. In the first of what will be a regular column on the topics by law firm Taylor Wessing, Paul England explores current developments on issues such as costs and judges.

SPCs: Questions of validity

EU, UK19-02-2015Michael Pitzner-Bruun

The tussle between Teva and Amgen over the latter’s SPC for lipegfilgrastim is still playing out in Denmark’s IP court and may yet be referred to the CJEU. Michael Pitzner-Bruun of law firm Kromann Reumert reports.

The bitter pill of fake medicine

International30-01-2015

The most recent Illicit Trade Report states that pharmaceuticals are by far the most numerous counterfeit commodity reported, and the problem is increasing. LSIPR investigates what’s being done about it.

Global patents: innovation leads to growth

International30-01-2015Bob Stembridge

Despite the headwinds facing the industry, a growing number of leading pharmaceutical companies feature on Thomson Reuters’ annual Top 100 Global Innovators list, as Bob Stembridge reports.

Repurposed drugs: second time lucky

EU19-12-2014Simon Kremer and Rachel Jones

Bringing a ‘repurposed’ drug to market requires a clear patent strategy, but clarity is unfortunately lacking in this field, say Simon Kremer and Rachel Jones of law firm Mewburn Ellis.

Marketing authorisation: the right to challenge

EU19-12-2014Trevor Cook

A decision by the CJEU on a Latvian case should make it easier in the future to challenge an MA granted for a generic version of a reference product, as Trevor Cook of WilmerHale explains.

University of Manchester IP: walk the line

UK, US28-11-2014

By facilitating public access to the work being done, universities face the challenge of maintaining a balance between being transparent and commercialising IP. LSIPR spoke to the head of the University of Manchester IP about walking the fine line.

IPEC: the right forum for life sciences?

UK27-11-2014Mark Didmon and Simon Curtis

The UK Intellectual Property Enterprise Court offers a quick and cheap way to resolve IP disputes, but very few have involved life sciences inventions. Mark Didmon and Simon Curtis of Potter Clarkson ask whether IPEC is an appropriate forum for handling these types of patent disputes.

Tomato and Broccoli: patenting plant products

EU, Germany27-11-2014Franz-Josef Zimmer and Markus Grammel

The EPO’s Enlarged Board of Appeal is about to deliver its long-awaited final decision on the patentability of plants, in the hope that it will at least bring legal certainty to patentees and unfreeze pending appeals. Franz-Josef Zimmer and Markus Grammel of Grünecker report.

Clinical trial data: a culture of transparency

EU25-11-2014

A new EU policy will require pharmaceutical companies to provide clinical trial data when seeking marketing approval for their drugs. But how will they ensure adequate IP protection while embracing the new culture of transparency? LSIPR reports.

Showing 201 to 210 of 272 results

LSIPR